SARS

A few additional treatment possibilities in COVID19 (SARS Cov-2) addressing furin-like cleavage and pyroptosis (caspacin-1 activation of inflammasome NLRP3)

COVID-19, Functional Medicine for Professionals5 Comments

The cytokine storm seen in SARS Cov1 and Cov2 might be due to chronic pyroptosis activation. However, known activators of NLRP3 in SARS-CoV differ from CoV2.  While SARS Cov1 and COVID19 are genetically very similar, the extraordinarily high rate of infectivity of COVID19 is unique. Prepublication research suggests the cause might be a unique furin-like cleavage site on the spike protein of Cov2 that was absent in Cov1.  

Eosinophilic Esophagitis

Eosinophilic Esophagitis in a 16yo Female: A Case Report

Case Studies, Functional Medicine for Professionals2 Comments

Allie was 16 years old when she first presented in my office with episodic abdominal pain in the lower right quadrant, onset 6 weeks prior, ranging from 2 to 10 on a visual analog pain scale (0=no pain, 10=worst possible pain). Her pain was not associated with reflux, fever, or blood in her stools. Allie had a prior diagnosis of eosinophilic esophagitis (EE), however treatment with diet and a proton pump inhibitor had not been successful.

Plasmalogen Deficiency, Dementia, and Death with Dr. Dayan Goodenowe

Plasmalogen Deficiency, Dementia, and Death with Dr. Dayan Goodenowe

Functional Medicine for Professionals9 Comments

Dr. Goodenowe invented a technology platform in 1999 that has been used to analyze thousands of human samples from around the world. Through collaborations with international researchers and doctors, Dr. Goodenowe has become an expert on the biochemical basis of neurological diseases including Alzheimer’s, Parkinson’s, multiple sclerosis, autism, bipolar disorder, and schizophrenia. Prodrome Sciences uses Dr. Goodenowe’s technology and discoveries to develop blood tests and dietary supplements for the early detection and prevention of disease.

Pathogenic Mechanisms of Lp(a)

The Lp(a) Conundrum

Functional Medicine for Professionals6 Comments

Lp(a): What do with DO with it? It’s an unequivocal CV risk marker, and its pathogenic mechanisms are multiple and far-reaching. Yet it’s notoriously refractory to treatment – pharma and FxMed. Get the low-down in this month’s blog: The Lp(a) Conundrum. As you will read in the blog opener, figuring out this conundrum is near and dear to my heart. Shout out to Ann Sims, RD, LD, CDE, CLS for support writing and providing references. Ann also suggested I podcast on NFFM with lipidologist Dr. Thomas Dayspring- we’re coordinating that as I type, so stay tuned. I’d love to hear from you on this one: how are you approaching Lp(a) in practice? Thank you! ~DrKF